サンプル依頼リスト カート
  • English
  • Korean
表紙：脂質異常症治療薬市場：薬剤クラス別、用途別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2023年～2030年
市場調査レポート
商品コード
1388770

脂質異常症治療薬市場：薬剤クラス別、用途別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2023年～2030年

Dyslipidemia Drugs Market, By Drug Class, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 269 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
脂質異常症治療薬市場：薬剤クラス別、用途別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2023年～2030年
出版日: 2023年11月01日
発行: AnalystView Market Insights
ページ情報: 英文 269 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

脂質異常症治療薬の市場規模は2022年に156億5,343万米ドルとなり、2023～2030年にCAGR 5.5%で拡大

脂質異常症は患者の間で蔓延している疾患であり、心血管疾患の発症と進行に重大なリスクをもたらします。これらの疾患は、総コレステロール（TC）、トリグリセリド（TG）、低比重リポ蛋白コレステロール（LDL-C）の上昇を特徴とします。脂質異常症治療薬として知られる薬剤は、血液中の脂質（脂肪）レベルの異常によって定義されるこの病状を治療するために利用されます。コレステロール値を下げる治療の基本は、スタチン、エゼチミブ、PCSK9阻害薬などの従来の脂質低下療法（LLT）と健康的なライフスタイルの維持です。スタチン系薬剤は、HMG-CoA還元酵素を選択的に阻害することにより、細胞内のコレステロール量を減少させます。

脂質異常症治療薬市場-市場力学

座りがちなライフスタイル、不健康な食生活、肥満の増加

脂質異常症の発症率は、座りがちなライフスタイル、不健康な食生活、肥満などの要因により増加しています。この動向は、社会経済の発展によりライフスタイルがさらに変化するにつれて、今後も続くと予想されます。独立行政法人製品評価技術基盤機構によると、脂質異常症の有病率は現在66.7％で、LDL-C高値が49.5％、トリグリセリド高値が40.2％、総コレステロール高値が30.8％、HDL-C低値が16.5％となっています。脂質異常症治療薬市場は、効果的な治療法に対する需要の高まりを受けて成長すると予想されます。さらに、薬剤の製剤や作用機序の革新により、新規薬剤や強化された薬剤が期待されます。しかし、代替療法が利用可能であることが市場成長の妨げになる可能性があります。

脂質異常症治療薬市場-セグメンテーション分析：

脂質異常症治療薬の世界市場は薬剤クラス別、用途別、地域別に区分されます。

薬剤クラス別に市場は2つに分類される：非スタチン系薬剤とスタチン系薬剤です。スタチン系薬剤は、脂質異常症の治療薬として処方されることが多く、特にコレステロール値の上昇を抑制する効果が高いです。一般に悪玉コレステロールとして知られるLDL（低比重リポ蛋白）コレステロールを減少させる効果が高いため、脂質異常症の治療薬として最も多く処方されています。

市場は用途別に3つのカテゴリーに分けられる：病院薬局、小売薬局、その他。病院薬局が市場を独占脂質異常症を含む心血管疾患の患者は、病院薬局で初期治療や継続的な治療を受けることが多いため、脂質異常症治療薬の管理と応用は病院環境において最も重要です。

脂質異常症治療薬市場-地理的洞察

この市場は北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにまたがっています。これらの地域は、商業をもたらす国々に基づいてさらに細分化されます。バイオテクノロジーの進歩やヘルスケア施設のアップグレードにより、北米は脂質異常症治療薬市場の拡大をリードする可能性が高いです。北米のヘルスケアインフラは高度に発達し、技術的にも進んでいるため、脂質異常症などのさまざまな病状の効果的な診断、治療、管理が容易になっています。The U.S. Health Care from a Global Perspectiveによると、2021年、米国はGDPの17.8%を医療に費やしており、これはOECD諸国の中央値の約2倍です。また、この地域にはバイオテクノロジー企業や製薬企業がかなり集中しており、現在、大規模な研究開発活動が行われています。欧州は脂質異常症治療薬の研究開発への投資が拡大しているため、脂質異常症治療薬市場規模は第2位です。

脂質異常症治療薬市場-競合情勢：

医薬品マーケティングサービス（PMS）は、製薬企業と医師とのつながりを構築するため、製薬企業にとって不可欠な存在です。また、国内外を問わず、医師と患者の橋渡しをする役割も担っています。脂質異常症治療薬の競合情勢には、著名な製薬会社、主要製品、市場シェア、この病状に対処する戦略などが含まれます。この競争市場では、より効果的で安全な医薬品を生み出すための絶え間ない研究開発努力、医師や患者に影響を与えるための積極的なマーケティングキャンペーン、市場支配力を強化するための戦略的提携などが戦略として挙げられます。

目次

第1章 脂質異常症治療薬市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 脂質異常症治療薬の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 脂質異常症治療薬産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 脂質異常症治療薬市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 脂質異常症治療薬市場情勢

  • 脂質異常症治療薬市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 脂質異常症治療薬市場：薬剤クラス別

  • 概要
    • 薬剤クラス別のセグメントシェア分析
    • 非スタチン系薬剤
      • 胆汁酸封鎖剤
      • コレステロール吸収阻害剤
      • フィブラーテス系
      • ニコチン酸
      • その他
    • スタチン系薬剤
      • 高強度
      • 中強度
      • 低強度

第8章 脂質異常症治療薬市場：用途別

  • 概要
    • 用途別のセグメントシェア分析
    • 病院薬局
    • 小売薬局
    • その他

第9章 脂質異常症治療薬市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東とアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第10章 主要ベンダー分析：脂質異常症治療薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Novartis AG
    • Mylan NV
    • Bristol-Myers Squibb Company
    • AstraZeneca plc
    • Shionogi &Co., Ltd.
    • Pfizer, Inc.
    • Abbott Laboratories.
    • Merck &Co., Inc.
    • Bayer AG
    • Amgen, Inc.

第11章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Dyslipidemia Drugs Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Dyslipidemia Drugs Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Dyslipidemia Drugs Market: Application Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Dyslipidemia Drugs Market, by Application 2018-2030 (USD Million)
  • TABLE Dyslipidemia Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Dyslipidemia Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Europe Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Asia Pacific Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Latin America Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)

List of Figures

  • FIGURE Dyslipidemia Drugs Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Drug Class segment market share analysis, 2022 & 2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Application segment market share analysis, 2022 & 2030
  • FIGURE Application segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE Europe Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE Asia Pacific Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE Latin America Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE Middle East and Africa Dyslipidemia Drugs Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Dyslipidemia Drugs Market share analysis by country, 2022
  • FIGURE Germany Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Dyslipidemia Drugs Market share analysis by country, 2022
  • FIGURE India Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Dyslipidemia Drugs Market share analysis by country, 2022
  • FIGURE Brazil Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Dyslipidemia Drugs Market share analysis by country, 2022
  • FIGURE Saudi Arabia Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Dyslipidemia Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
目次
Product Code: ANV1824

REPORT HIGHLIGHT

Dyslipidemia Drugs Market size was valued at USD 15,653.43 Million in 2022, expanding at a CAGR of 5.5% from 2023 to 2030.

Dyslipidemias, prevalent disorders among patients, pose significant risks for the development and progression of cardiovascular diseases. These disorders are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). Medications known as dyslipidemia drugs are utilized to treat this medical condition, which is defined by abnormal lipid (fat) levels in the bloodstream. The cornerstone of treatment to lower cholesterol levels involves conventional lipid-lowering therapies (LLTs), such as statins, ezetimibe, and PCSK9 inhibitors, in conjunction with maintaining a healthy lifestyle. Statins work by reducing cellular cholesterol content through the selective inhibition of the enzyme HMG-CoA reductase.

Dyslipidemia Drugs Market- Market Dynamics

Increasing Prevalence of sedentary lifestyles, unhealthy dietary habits, and obesity

The incidence of dyslipidemia has increased due to factors such as sedentary lifestyles, unhealthy dietary habits, and obesity. This trend is expected to continue as socio-economic development leads to further lifestyle changes. According to the National Center for Biotechnological Information, the prevalence of dyslipidemia is currently at 66.7%, with high LDL-C, elevated triglyceride, elevated total cholesterol, and low HDL-C being prevalent in 49.5%, 40.2%, 30.8%, and 16.5% of cases, respectively. The dyslipidemia drugs market is expected to grow to meet the rising demand for effective treatments. Furthermore, Innovations in drug formulations and mechanisms of action present prospects for novel and enhanced medications. However, the availability of alternative therapies may hamper the market growth.

Dyslipidemia Drugs Market- Key Insights

  • As per the analysis shared by our research analyst, the global Dyslipidemia Drugs market is estimated to grow annually at a CAGR of around 5.5% over the forecast period (2023-2030)
  • The demand for dyslipidemia treatments is expected to grow significantly due to Increasing Prevalence of sedentary lifestyles, unhealthy dietary habits, and obesity
  • Based on Drug Class segmentation, statins drugs were predicted to show maximum market share in the year 2022
  • Based on Application segmentation, Hospital pharmacy was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Dyslipidemia Drugs Market- Segmentation Analysis:

The Global Dyslipidemia Drugs Market is segmented on the basis of Drug Class, Application, and Region.

The market is divided into two categories based on Drug Class: Non-statins drugs and statins drugs. statins drugs dominate the market. Statins are frequently prescribed drugs for the treatment of dyslipidemia, particularly in the management of elevated levels of cholesterol. They are highly effective in reducing LDL (low-density lipoprotein) cholesterol, commonly known as bad cholesterol, and are therefore one of the most commonly prescribed medications for this condition.

The market is divided into three categories based on Application: Hospital pharmacy, Retail pharmacy, and Others. Hospital pharmacy dominates the market. The management and Application of dyslipidemia drugs are of utmost importance in hospital settings, as patients with cardiovascular conditions, including dyslipidemia, often receive their initial or ongoing treatment from hospital pharmacies.

Dyslipidemia Drugs Market- Geographical Insights

This market is extensive over North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. These areas are further subdivided based on the countries bringing commerce. Because of biotechnological advancements and upgrades in healthcare facilities North America is likely to lead in the expansion of the Dyslipidemia Drugs market. The healthcare infrastructure in North America is highly developed and technologically advanced, facilitating the effective diagnosis, treatment, and control of a range of medical conditions, such as dyslipidemia. The U.S. Health Care from a Global Perspective showed that in 2021, the U.S. disbursed 17.8 % of GDP on medical care, nearly double as much as the median OECD nations. Also, there is a significant concentration of biotechnology and pharmaceutical firms in the area, which are currently involved in extensive research and development activities. Europe is the second largest Dyslipidemia Drugs market, due to growing investment in Research and development of Dyslipidemia Drugs.

Dyslipidemia Drugs Market- Competitive Landscape:

Pharmaceutical marketing services (PMS) are essential for pharmaceutical companies as they establish connections between the company and physicians. They also serve as a bridge between physicians and patients, both locally and globally. The competitive landscape of dyslipidemia drugs includes prominent pharmaceutical companies, their primary products, market share, and strategies to address this medical condition. In this competitive market, strategies involve continuous research and development efforts to create more effective and safer medications, assertive marketing campaigns to influence physicians and patients, and strategic collaborations to strengthen market dominance.

Recent Developments:

on July 2023, Novartis said that the US FDA had authorized a label modification for Leqvio (inclisiran) to allow for earlier usage as an addition to diet and statin treatment in patients with high LDL-C who are at greater risk of heart disease.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DYSLIPIDEMIA DRUGS MARKET KEY PLAYERS

  • Novartis AG
  • Mylan N.V.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Shionogi & Co., Ltd.
  • Pfizer, Inc.
  • Abbott Laboratories.
  • Merck & Co., Inc.
  • Bayer AG
  • Amgen, Inc.

GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY DRUG CLASS

  • Non-statins drugs
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitor
  • Fibrates
  • Nicotinic Acid
  • Others
  • Statin drugs
  • High intensity
  • Moderate intensity
  • Low intensity

GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY APPLICATION

  • Hospital pharmacy
  • Retail pharmacy
  • Others

GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Dyslipidemia Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Dyslipidemia Drugs Market Snippet by Drug Class
    • 2.1.2. Dyslipidemia Drugs Market Snippet by Application
    • 2.1.3. Dyslipidemia Drugs Market Snippet by Country
    • 2.1.4. Dyslipidemia Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Dyslipidemia Drugs Key Market Trends

  • 3.1. Dyslipidemia Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Dyslipidemia Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Dyslipidemia Drugs Market Opportunities
  • 3.4. Dyslipidemia Drugs Market Future Trends

4. Dyslipidemia Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Dyslipidemia Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Dyslipidemia Drugs Market Landscape

  • 6.1. Dyslipidemia Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Dyslipidemia Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 7.1.2. Non-statins drugs
      • 7.1.2.1. Bile Acid Sequestrants
      • 7.1.2.2. Cholesterol Absorption Inhibitor
      • 7.1.2.3. Fibrates
      • 7.1.2.4. Nicotinic Acid
      • 7.1.2.5. Others
    • 7.1.3. Statin drugs
      • 7.1.3.1. High intensity
      • 7.1.3.2. Moderate intensity
      • 7.1.3.3. Low intensity

8. Dyslipidemia Drugs Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
    • 8.1.2. Hospital pharmacy
    • 8.1.3. Retail pharmacy
    • 8.1.4. Others

9. Dyslipidaemia Drugs Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Dyslipidemia Drugs Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Dyslipidemia Drugs Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Dyslipidemia Drugs Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Dyslipidemia Drugs Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Dyslipidemia Drugs Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Dyslipidemia Drugs Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Novartis AG
    • 10.2.2. Mylan N.V.
    • 10.2.3. Bristol-Myers Squibb Company
    • 10.2.4. AstraZeneca plc
    • 10.2.5. Shionogi & Co., Ltd.
    • 10.2.6. Pfizer, Inc.
    • 10.2.7. Abbott Laboratories.
    • 10.2.8. Merck & Co., Inc.
    • 10.2.9. Bayer AG
    • 10.2.10. Amgen, Inc.

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us